您当前的位置:
首页 >
文章列表页 >
Preclinical pharmacological studies of 131I-FP-β-CIT as dopamine transporter imaging agent
更新时间:2021-03-12
    • Preclinical pharmacological studies of 131I-FP-β-CIT as dopamine transporter imaging agent

    • NUCLEAR TECHNIQUES   Issue 11, (2003)
    • CLC: R96
    • Published:01 November 2003

    移动端阅览

  • CHEN Zhengping ZHOU Xiang DING Shiyu LIN Yansong TANG Jun WANG Feng WUChunying JI Shuren LU Chunxiong FANG Ping. Preclinical pharmacological studies of 131I-FP-β-CIT as dopamine transporter imaging agent[J]. Nuclear techniques, 2003, (11): 858-862. DOI:

  •  
  •  

0

Views

20

下载量

2

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Acupuncture improve motor function in a mouse model of Parkinson’s disease
Exploration of central dopamine transporter and D2 receptor in morphine abstinent rats
Clinical application of 99TCm-TRODAT-1 SPECT imaging of dopamine transporter in monitoring the state of Parkinson’s disease
Synthesis and labeling of 125/131I-FP-β-CIT as a dopamine transporter imaging agent
Density changes in striatal dopamine transporters and D2 receptors in MPTP treated mouse model

Related Author

孙艳红
王璐
张一
诸颖
李晓明
孔华庭
王少朋
胡钧

Related Institution

Laboratory of Physical Biology,Shanghai Institute of Applied Physics,Chinese Academy of Sciences,Jiading Campus
Peking Union Medical College Hospital, Beijing 100730) 2
北京协和医院核医学科
Department of Nuclear Medicine, the First Affiliated Hospital of Zhongshan University
中山大学附属第一医院核医学科
0